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Abstract
Bone homeostasis is maintained through a balance between osteoblastic bone formation and osteoclastic bone
resorption. Aging induces bone loss due to decreased osteoblastic bone formation and increased osteoclastic bone
resorption. Osteoporosis with its accompanying decrease in bone mass is widely recognized as a major public
health problem. Nutritional factors may play a role in the prevention of bone loss with aging. Among various
carotenoids (carotene and xanthophylls including beta (b)-cryptoxanthin, lutein, lycopene, b-carotene, astaxanthin,
and rutin), b-cryptoxanthin, which is abundant in Satsuma mandarin orange (Citrus unshiu MARC.), has been found
to have a stimulatory effect on bone calcification in vitro. b-cryptoxanthin has stimulatory effects on osteoblastic
bone formation and inhibitory effects on osteoclastic bone resorption in vitro, thereby increasing bone mass. b-
cryptoxanthin has an effect on the gene expression of various proteins that are related osteoblastic bone formation
and osteoclastic bone resororption in vitro. The intake of b-cryptoxanthin may have a preventive effect on bone
loss in animal models for osteoporosis and in healthy human or postmenopausal women. Epidemiological studies
suggest a potential role of b-cryptoxanthin as a sustainable nutritional approach to improving bone health of
human subjects. b-Cryptoxanthin may be an osteogenic factor in preventing osteoporosis in human subjects.
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Introduction
Bone is a dynamic tissue that preserves skeletal size,
shape, and structural integrity and to regulate mineral
homeostasis. Bone homeostasis is maintained through a
balance between osteoblastic bone formation and osteo-
clastic bone resorption. Aging and numerous pathologi-
cal processes induce decrease in bone formation and
increase in bone resorption, leading to osteoporosis, a
devastating bone disease [1]. Osteoporosis, which is
induced with decrease in bone mass, is widely recog-
nized as a major public health problem [1]. The most
dramatic expression of the disease is represented by
fractures of the proximal femur for which the number
increases as the population ages [2].
Nutritional factors may have the potential effect to
prevent bone loss with increasing age. There is growing
evidence that the supplementation of nutritional and
food factors may have the preventive effect on bone loss
that is induced in animal model of osteoporosis and in
human subjects [3-6]. Chemical compounds in food and
plants, which regulate on bone homeostasis, have been
to be worthy of notice in maintaining of bone health
and prevention of bone loss with increasing age [7-13].
Carotenoids (carotene and xanthophyll) are present in
fruit and vegetables. Carotenoids, which are a provita-
min A, may have an anabolic effect on bone metabo-
lism. Vitamin A (retinol, retinal, and retinoic acid),
which is formed from carotenoids in animal and human,
has been shown to have a role in the regulation of bone
cells and it may have an anabolic effect on bone [14-16].
However, vitamin A is also known to have a detrimental
effect on bone at high doses [17-20]. In laboratory ani-
mals, high levels of vitamin A lead to accelerated bone
resorption, bone fractures, and osteoporotic bone lesions
[17].
Beta (b)-cryptoxanthin, a kind of xanthophyll, is abun-
dant in Satsuma mandarin orange (Citrus unshiu
MARC.). Of various carotenoids, b-cryptoxanthin has
been found to have a potential-anabolic effect on bone
due to stimulating osteoblastic bone formation and inhi-
biting osteoclastic bone resorption [21,22]. This review
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cerning the role of b-cryptoxanthin in the regulation of
bone homeostasis and in the prevention of osteoporosis,
especially the cellular and molecular mechanisms by
which b-cryptoxanthin stimulates osteoblastic bone for-
mation and inhibits osteoclastic bone resorption.
Effect of carotenoids in bone homeostasis
Bone is a dynamic tissue that undergoes continual adap-
tation during vertebrate life to attain and preserve skele-
tal size, shape, and structural integrity and to regulate
mineral homeostasis. Bone homeostasis is regulated by
the functions of osteoblasts, osteoclasts, and osteocytes
which are major cells in bone tissues [23,24]. Osteo-
clasts, which develop from hematopoietic progenitors,
are recruited to the site and excavate the calcified
matrix. Osteoblasts arising from local mesenchymal
stem cells assemble at the bottom of the cavity and
bone formation begins. Bone acts as major storage site
for growth factors [25]. Growth factors, which are pro-
duced by osteoblasts, diffuse into newly deposited
osteoid and are stored in the bone matrix including isu-
lin-like growth factors (IGF- I and II), transforming
growth factor-b1( T G F - b1), platelet-derived growth fac-
tor (PDGF), and bone morphologic protein (BMP).
These bone-derived factors, which can be liberated dur-
ing subsequent periods of bone resorption, act in an
autocrine, paracrine, or delayed paracrine fashion in the
local microenvironment of the bone surface. Thus, bone
homeostasis is regulated through complex mechanism.
Whether functional food factors can regulate bone
homeostasis has been poorly understood.
Carotene, which is contained in plant and fruits, is
generically named for carotene (a, b, g, δ, ε)a n dl y c o -
pene, which is a natural compound with the derivative
of fundamental form of C40H56 in chemical structure.
Other derivatives with hydroxyl group for C40H56 are
named as xanthophyll, which are lutein, zeaxanthin,
canthaxanthin, fucoxanthin, antheraxanthin, violax-
anthin, and b-cryptoxanthin. Carotenoids are named
generically for carotene and xanthophyll.
The effects of carotenes, canthaxanthin, fucoxanthin,
antheraxanthin, and violaxanthin on bone homeostasis
have not been shown clearly. Among various carotenes
and xanthophylls (including b-carotene, lycopene, lutein,
astaxanthin, and b-cryptoxanthin), b-cryptoxanthin has
been found to have a potential-anabolic effect on bone
calcification in vitro [21,22]. Myricetin, kaempferol, iso-
rhamnetin, curcumin, hesperidin, and rutin (quercetin-
3-rutinoside) of various flavonoids do not have an effect
on bone formation and calcification in vitro [22].
Vitamin A (retinol, retinal, and retinoic acid) is
formed from carotenoids, which are provitamin A, in
the animals and humans. The retinoic acid receptors
(RAR) a, b and g (RARa,R A Rb and RARg) are nuclear
hormone receptors that regulate fundamental processes
during embryogenesis, but their roles in skeletal devel-
opment and growth are investigated.
Mice deficient in RARa and RARg (or RAR b and
RARg) have been shown to exhibit severe growth retar-
dation obvious by about 3 weeks postnatally [14]. Reti-
noic acid receptors may be required for skeletal growth,
matrix homeostasis and growth plate function in postna-
tal mouse, suggesting a role of retinoic acid in bone
growth [14].
Retinol and b-carotene have been shown to inhibit the
proliferation of MC3T3-E1 cells as well as DNA synth-
esis of the cells in a dose-dependent manner [15] and
stimulate differentiation of MC3T3-E1 cells by increas-
ing alkaline phosphatase activity dose dependently [15].
a-Carotene, canthaxanthin, and lycopene also have been
shown to inhibit MC3T3-E1 cell proliferation and to
increase alkaline phosphatase activity and osteopontin
mRNA expression [15].
The effects of retinoids on osteoclast differentiation in
cultured mouse bone marrow cells (BMCs), bone mar-
row macrophages (BMMs), spleen cells, and RAW264.7
cells are shown by analyzing osteoclast formation and
expression of important genes in signal transduction
and osteoclast function [16]. All-trans-retinoic acid
(ATRA) did not stimulate osteoclastogenesis in BMCs,
but inhibited hormone and RANK (receptor activator of
nuclear factor kappa B; NF-B) ligand (RANKL)-
induced gene expression and formation of osteoclasts
[16]. ATRA abolished an increase in the transcription
factors c-Fos and the nuclear factor of activated T cells
(NFAT) NFAT2 stimulated by RANKL and suppressed
down-regulation of the anti-osteoclastogenic transcrip-
tion factor MafB [16].
Excessive intakes of vitamin A have been shown to
have adverse skeletal effects in animals [17]. High vita-
min A intake may lead to an increased risk of fracture
in humans. Association between vitamin D deficiency
and excess of vitamin A as a potential risk factor of
osteoporosis and fracture is shown [18]. Whereas in
women with vitamin D deficiency the risk of osteoporo-
s i si n c r e a s e dw a su p5t i m e sh i g h e rt h a nw o m e ni nt h e
lowest quintile of retinol [18]. High retinol levels
together with vitamin D deficiency may be hitherto an
overlooked risk factor for osteoporosis.
Retinol is derived from both retinoids, which are con-
tained in animal food, and carotenoids, which are con-
tained in vegetables and fruits. A possible role of
carotenoids in involutional osteoporosis is evaluated.
When plasma levels of b-carotene and other carote-
noids, in addition to those of retinol, were measured in
free-living, non-supplemented, elderly women with or
without severe osteoporosis, plasma levels of retinol and
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were consistently lower in osteoporotic than in control
women [26]. A weak association was found only
between retinol and femoral neck bone mineral density
in osteoporotic women [26]. A bone sparing effect of
retinol, to which the provitamin A activity of some caro-
tenoids, may be contributed [26].
Carotenoid lycopene has been shown to have an inhi-
bitory effect on bone resorption in vitro [27], although
lycopene is not shown to have a stimulatory effect on
mineralization using rat femoral tissues in vitro [21].
Lycopene (10
-5 M) has been found to inhibit basal and
parathyroid hormone (PTH)-stimulated osteoclastic
mineral resorption and formation of tartrate-resistant
acid phosphatase (TRAP) activity-possitive multinu-
cleated osteoclasts [27]. Lycopene may have an inhibi-
tory effect on osteoclastic bone resorption, suggesting
that lycopene has a role in the prevention of
osteoporosis.
In a cross-sectional study by using 33 postmenopausal
women aged 50-60 years, groups with higher lycopene
intake, as determined from the dietary records, showed
higher serum lycopene [28]. A higher serum lycopene
has been found to be associated with a low cross-linked
N-telopeptides of type I collagen [28]. Similarly, groups
with higher serum lycopene have lower protein oxida-
tion [28]. These observations suggest that the dietary
antioxidant lycopene reduces oxidative stress and the
levels of bone turnover markers in postmenopausal
women, and may be beneficial in reducing the risk of
osteoporosis [28].
Postmenopausal women supplemented with lycopene
are shown to increase antioxidant capacity and decrease
oxidative stress and the bone resorption marker N-telo-
peptide [29]. Lycopene decreases bone resorption mar-
kers and may reduce the risk of osteoporosis [29]. Sixty
postmenopausal women, 50-60 years old, were recruited
[29]. Following a 1-month washout without lycopene
consumption, participants consumed either regular
tomato juice, lycopene-rich tomato juice, tomato lyco-
pene capsules, or placebo capsules, twice daily for total
lycopene intakes of 30 and 70 mg/day respectively for 4
months [29]. Lycopene supplementation for 4 months
significantly increased serum lycopene and decreased
lipid peroxidation, and cross-linked aminoterminal N-
telopeptide as compared to placebo [29]. The antioxi-
dant lycopene may be beneficial in reducing oxidative
stress parameters and the bone resorption marker [29].
b-Cryptoxanthine and bone homeostasis
Xanthophyll b-cryptoxanthin, which is a kind of carote-
noid, is abundant in Satsuma mandarin orange (Citrus
unshiu MARC). The molecular weight of b-cryptox-
anthin is 552. The biological function of b-
cryptoxanthin in animal and human, however, has been
not determined fully. Yamaguchi et al. found that b-
cryptoxanthin has been shown to have a unique ana-
bolic effect on bone calcification; such an effect is not
seen in lutein, lycopene, or astaxanthin, which is other
carotenoids and flavonoid rutin (quercetin-3-rutinoside)
[21,22].
b-Cryptoxanthin stimulates bone formation and inhibits
bone resorption in bone tissue culture
b-Cryptoxanthin has been shown to have a unique ana-
bolic effect on bone calcification. Culture with b-cryp-
toxanthin (10
-7 or 10
-6 M) has been found to cause an
increase in calcium content and alkaline phosphatase
activity in the femoral-diaphyseal (cortical bone) and
-metaphyseal (trabecular bone) tissues in vitro.L u t e i n ,
lycopene, and rutin (10
-8 to 10
-6 M) did not have ana-
bolic effects on alkaline phosphatase activity and cal-
cium contents in rat femoral tissues [21]. Astaxanthin
and b-carotene did not have an effect on the femoral
calcium contents [22]. Myricetin, kaempferol, isorham-
netin, curcumin, or hesperidin (10
-7 to 10
-5 M) had no
effect on bone calcium content in tissue cultures in
vitro [22]. Quercetin significantly increased calcium con-
tent in femoral diaphyseal tissues but not metaphyseal
tissues. b-Cryptoxanthin has a unique anabolic effect on
bone calcification in vitro. The effect of b-cryptoxanthin
increasing bone components was completely prevented
in the presence of cycloheximide, an inhibitor of protein
synthesis, suggesting that the effect is needed newly pro-
tein synthesis [22].
b-Cryptoxanthin has also been shown to inhibit bone
resorption in bone tissue cultures in vitro [22]. Parathyr-
oid hormone (PTH) or prostaglandin E2 (PGE2), which
is a bone-resorbing factor, can stimulate osteoclastic
bone resorption in vitro [30-32]. Culture with PTH or
PGE2 caused a decrease in calcium content in the dia-
physeal and metaphyseal tissues [22]. This decrease was
completely inhibited in the presence of b-cryptoxanthin
(10
-8 to 10
-6 M). Likewise, culture with b-cryptoxanthin
completely inhibited the PTH- or PGE2-induced
increase in medium glucose consumption and lactic acid
production by bone tissues [22]. b-Cryptoxanthin has an
inhibitory effect on bone resorption in tissue culture in
vitro.
Thus, b-cryptoxanthin has been shown to have stimu-
latory effect on osteoblastic bone formation and inhibi-
tory effects on osteoclastic bone resorption in bone
tissue culture in vitro. Serum concentration of b-cryp-
toxanthin due to consumption of vegetable juice in
women is shown to be in the range of 1.3 × 10
-7 to 5.3
×1 0
-7 M [33]. b-Cryptoxanthin in the range of 10
-8 to
10
-6 M has an anabolic effect on biochemical compo-
nents in rat femoral tissues in vitro, suggesting a physio-
logic role in the regulation of bone metabolism.
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The cellular and molecular mechanisms by which b-
cryptoxanthin stimulates bone formation in bone tissues
has been examined by using osteoblastic MC3T3-E1
cells in vitro. b-Cryptoxanthin has been found to stimu-
late the proliferation of osteoblastic cells in subconfluent
monolayers in a medium containing 10% fetal bovine
serum [34]. Culture with b-cryptoxanthin also caused an
increase in biochemical components (alkaline phospha-
tase activity, protein, and DNA contents) of osteoblastic
cells [34]. This effect was abolished in the presence of
staurosporine, an inhibitor of protein kinase C, or
PD98059, an inhibitor of mitogen- activated protein
kinase (MAPK), although the effect of b-cryptoxanthin
in increasing cellular biochemical components was not
prevented in culture with dibucain, an inhibitor of Ca
2
+/calmodulin-dependent protein kinase [34]. The stimu-
latory effect of b-cryptoxanthin on osteoblastic cell com-
ponents seems to be partly mediated through signaling
factors of protein kinase C or MAPK in the cells.
The effects of b-cryptoxanthin in increasing the bio-
chemical components in osteoblastic cells were comple-
tely inhibited in the presence of 5,6-dichloro-1- b-D-
ribofuranosylbenzimidazole (DRB), an inhibitor of RNA
polymerase II, suggesting that the effect of carotenoid
results from a stimulatory effect on transcriptional activ-
ity in osteoblastic cells.
The mineralization in osteoblastic cells is shown to
stimulate in the prolonged culture with b-cryptoxanthin
[35]. The stimulatory effect of b-cryptoxanthin on
mineralization may result from the carotenoid-induced
proliferation and differentiation of osteoblastic cells.
b-Cryptoxanthin may stimulate gene expression for
proteins that are involved in bone formation and miner-
alization in osteoblastic cells. The effect of b-cryptox-
anthin on gene expression in osteoblastic cells using
reverse transcription-polymerase chain reaction (RT-
PCR) is examined. Culture with b-cryptoxanthin was
found to stimulate the mRNA expression of IGF-I or
TGF- b1 in osteoblastic cells [34]. This finding may sup-
port the view that b-cryptoxanthin has a stimulatory
effect on transcriptional activity in osteoblastic cells.
IGF-I or TGF-b1 is a bone growth factor produced from
osteoblasts [36-38]. The stimulatory effect of b-cryptox-
anthin on the proliferation of osteoblastic cells may be
partly mediated through the action of IGF-I or TGF-b1
produced from the cells.
TGF-b1 has a potent activity on osteoblast-lineage
commitment an event that is partly mediated through
Smad transcription factors [38]. It has been reported
that NF-B signaling represses basal osteoblast differen-
tiation and mineralization in MC3T3 cells and antago-
nizes TGF-b1a n dB M P - 2m e d i a t e dM C 3 T 3
mineralization by downregulating Smad activation [39].
Interestingly, b-cryptoxanthin has been shown to have
the capacity to suppress the receptor activator of nuclear
factor-kappa B (NF-B) activity in MC3T3 preosteoblas-
tic cells [40], suggesting that one mechanism by which
b-cryptoxanthin may stimulate osteoblast differentiation
may be by promoting Smad activation. This finding also
suggests that b-cryptoxanthin may lead to enhanced
Smad signaling. While, b-cryptoxanthin failed to directly
stimulate Smad activity, it did however amplify TGF-b1-
induced Smad signaling [41].
Furthermore, whether b-cryptoxanthin directly stimu-
lates Smad activation or regulates TGF-b1-induced
Smad activation in osteoblastic cells in vitro is examined
[41]. b-Cryptoxanthin was found to potentiate TGF-b1-
induced, but not BMP-2-induced, Smad activation in
MC3T3 preosteoblastic cells, suggesting that one
mechanism by which b-cryptoxanthin stimulates bone
formation is by potentiating the TGF-b1-mediated com-
mitment of preosteoblasts to differentiate along the
osteoblastic pathway [41].
Runx2 (Cbfa1) is a member of the runt domain family
of transcription factors and a master regulator of osteo-
blast differentiation [42]. a1 (I) Collagen is a matrix
protein that is related to bone formation and mineraliza-
tion in osteoblast lineage cells [43]. Alkaline phospha-
tase participates in the mineralization process in
osteoblastic cells [44]. b-Cryptoxanthin (10
-7 or 10
-6 M)
was found to increase the mRNA expression of Runx2,
a1 (I) collagen, and alkaline phosphatase in osteoblastic
MC3T3-E1 cells [35].b-Cryptoxanthin had a stimulatory
effect on the gene expression of various proteins
involved in osteoblasic bone formation [35]. Such effects
of b-cryptoxanthin were blocked in the presence of DRB
[34], supporting the view that the carotenoid stimulates
transcriptional activity in osteoblastic MC3T3-E1 cells.
Vitamin A (retinol) may be able to bind to nuclear
receptors in cells. Retinol and b-carotene has been
shown to inhibit the proliferation of osteoblastic
MC3T3-E1 cells as well as DNA synthesis of the cells,
due to increasing alkaline phosphatase activity dose
dependently (10
-9 to 10
-7 M) [15]. Vitamin A (10
-7 or
10
-6 M) increases alkaline phosphatase activity in
osteoblastic cells [34]. b-Cryptoxanthin (10
-7 or 10
-6
M) caused an increase in alkaline phosphatase activity
and protein content in osteoblastic cells. This effect
was also seen in the presence of vitamin A (10
-6 M)
[34]. Moreover, the stimulatory effect of b-cryptox-
anthin on the expression of Runx2 type 1 and a1( I )
collagen mRNA was observed in the presence of vita-
min A [34]. Vitamin A did not have a significant effect
on Runx2 type 1 mRNA expression in osteoblastic
MC3T3-E1 cells [34]. Thus, the mode of action of b-
cryptoxanthin on gene expression in osteoblastic cells
may differ from that of vitamin A, which is mediated
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of the cells [34].
It is speculated that b-cryptoxanthin can bind to other
receptors (including orphan receptors that ligands are
not unknown), and that the carotenoid may stimulate
transcriptional activity in osteoblastic cells. The mechan-
ism of b-cryptoxanthin action in stimulating prolifera-
tion, differentiation, and mineralization in osteoblastic
cells is summarized in Figure 1.
b-Cryptoxanthin suppresses osteoclastogenesis
NF-B ligand (RANKL) plays a pivotal role in osteoclas-
togenesis from bone marrow cells. RANKL expression is
induced in osteoblastic cells and bone marrow stromal
cells in response to osteoporotic factors, such as PTH,
PGE2, and 1,25-dihydroxyvitamin D3 (VD3), and com-
bined treatment of hematopoietic cells with macrophage
colony-stimulating factor (M-CSF) and the soluble form
of RANKL (sRANKL) induce osteoclast differentiation
in vitro [45,46]. The receptor protein RANK (receptor
activator of NF-B) is expressed on the surface of osteo-
clast progenitors.
b-Cryptoxanthin (10
-8 to 10
-6 M) is shown to have a
potent inhibitory effect on osteoclast-like cell forma-
tion in mouse marrow culture in vitro [47]. The inhibi-
tory effect of b-cryptoxanthin on osteoclast-like cell
formation was seen at the later stage of osteoclast dif-
ferentiation in bone marrow cultures [47]. Culture
with b-cryptoxanthin caused a marked inhibition of
osteoblast-like cell formation induced in the presence
of PTH, PGE2,V D 3, lipopolysaccharide, or tumor
necrosis factor-a (TNF-a). b-Cryptoxanthin also had
an inhibitory effect on osteoclast-like cell formation
induced by RANKL [47]. The inhibitory effect of b-
cryptoxanthin was equal to that of 17 b-estradiol (E2),
calcitonin, genistein, and zinc sulfate, which can inhibit
osteoclast-like cell formation induced by bone-resorb-
ing factors [47].
The interaction of RANKL with its receptor RANK
leads to the recruitment of the signaling adaptor mole-
cules TRAFs (TNF receptor-associated factors) to the
receptor complex and the activation of NF-B and c-Jun
N-terminal kinase (JNK) [48,49]. Protein kinase C family
enzyme has a role in regulation of osteoclast formation
and function potentially by participating in the extracel-
lular signaling-regulated kinase (ERK) signaling pathway
of M-CSF and RANKL [49].
Phorbol 12-myristate 13-acetate (PMA), an activator
of protein kinase C, stimulated osteoclast-like cell for-
mation in mouse marrow cultures, and the PMA-
induced osteoclastogenesis was found to inhibit in the
presence of b-cryptoxanthin [47]. Moreover, b-cryptox-
anthin had an inhibitory effect on dibutyryl cyclic ade-
nosine monophosphate (DcAMP)-induced osteoclast-
like cell formation in mouse marrow cultures [47]. It is
assumed that activation of protein kinase C and protein
kinase A pathways leads to increased RANKL expres-
sion, and that b-cryptoxanthin can inhibit protein kinase
C- or protein kinase A-related RANKL expression in
osteoclastogenesis.
The effect of b-cryptoxanthin on mature osteoclasts
is demonstrated [50]. M-CSF-dependent bone marrow
macrophages were cultured in the presence of M-CSF
and RANKL for 4 days [50]. The osteoclastic cells
formed were further cultured in medium containing
b-cryptoxanthin with or without M-CSF and RANKL
for 24-72 hours. The number of osteoclastic cells has
been found to decrease in culture with b-cryptox-
anthin (10
-7 or 10
-6 M) in the presence or absence of
M-CSF and RANKL for 72 hours. The b-cryptox-
anthin-induced decrease in osteoclastic cells was
inhibited in the presence of caspase-3 inhibitor. The
results of agarose gel electrophoresis showed the pre-
sence of low-molecular-weight DNA fragments of
adherent cells cultured with b-cryptoxanthin. These
findings indicate that the carotenoid induces apopto-
tic cell death.
Apoptosis-related gene expression was determined by
using RT-PCR [50]. The expression of caspase-3 mRNA
or Apaf-2, which involves apoptosis, in osteoclastic cells
was found to stimulate when cultured with b-cryptox-
anthin in the presence or absence of M-CSF and
RANKL [50]. b-Cryptoxanthin-induced apoptotic cell
death may be partly mediated through caspase-3 expres-
sion in osteoclastic cells.
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Figure 1 The cellular and molecular mechanism by which b-
cryptoxanthin (BCX) stimulates bone formation and
mineralization in osteoblastic cells. BCX may bind to orphan
receptors in the nucleus of osteoblastic cells, and it stimulates gene
expression of bone formation-related proteins. BCX also stimulates
nuclear transcriptional activity mediated through activation of
protein kinase C (PKC) or mitogen-activated protein kinase (MAPK)
in osteoblastic cells.
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the rescue of apoptosis, was decreased after culture with
b-cryptoxanthin in the presence or absence of M-CSF
and RANKL [50]. However, Akt-1 mRNA expression
was not significantly changed in culture with b-cryptox-
anthin. The decrease in Bcl-2 mRNA expression may
partly contribute to the effect of b-cryptoxanthin in sti-
mulating the apoptotic cell death of osteoclastic cells.
Culture with b-cryptoxanthin is found to have sup-
pressive effects on tartrate-resistant acid phosphatase
(TRACP) activity, and it decreases TRACP and cathe-
psin K mRNA expressions in osteoclastic cells in the
presence or absence of M-CSF and RANKL [50]. These
findings suggest that b-cryptoxanthin can inhibit the
enhancement of bone-resorbing activity in osteoclasts.
b-Cryptoxanthin inhibitd various bone-resorbing fac-
tors-induced decrease in bone calcium content and
increase in lactic acid production in rat femoral tisuue
culture system in vitro. Presumably, b-cryptoxanthin has
an inhibitory effect on the activation of mature
osteoclasts.
As mentioned above,b-cryptoxanthin has stimulatory
effects on apoptotic cell death due to activating gene
expression of its related proteins. The carotenoid also
has suppressive effects on TRACP activity and gene
expression of enzymes that involve in bone-resorbing
activity in osteoclastic cells. The action of b-cryptox-
anthin in osteoclasts is summarized in Figure 2.
Effect of b-cryptoxanthin on bone is synergistically
enhanced by zinc
Zinc, an essential trace element, has an anabolic effect
due to stimulating osteoblastic bone formation and
osteoclastic bone resorption in vitro and in vivo
[6,51-55]. The effect of the combination of b-cryptox-
anthin and zinc sulfate on bone components in the
femoral-diaphyseal and -metaphyseal tissues of young
rats in vitro is examined [56]. Bone tissues were cul-
tured for 48 hours in a serum-free medium containing
either vegicle, b-cryptoxanthin (10
-9-10
-7 M) or zinc sul-
fate (10
-6-10
-4 M). The presence of b-cryptoxanthin (10
-
9 M) or zinc (10
-6 M) did not have a significant effect
on calcium content in the femoral-diaphyseal or -meta-
physeal tissue [56]. However, culture with combination
of b-cryptoxanthin (10
-9 M) and zinc (10
-6 M) caused
an increase in calcium content in the femoral-diaphyseal
and -metaphyseal tissues. Such an effect was not
observed in the combination of b-cryptoxanthin (10
-9
M) plus genistein (10
-6 M) or menaquinone-7 (10
-6 M),
or zinc (10
-6 M) plus genistein (10
-6 M) or menaqui-
none-7 (10
-6 M) [56].
The combination of b-cryptoxanthin (10
-9 M) plus
zinc (10
-6 M) was found to cause a remarkable increase
in alkaline phosphatase activity and DNA content in the
diaphyseal and metaphyseal tissues, while their applica-
tion alone did not have an effect on the enzyme activity
or DNA content in the bone tissues [56]. The effect of
the combination of b-cryptoxanthin (10
-9 M) plus zinc
(10
-6 M) in increasing alkaline phosphatase activity,
DNA and calcium contents in the diaphyseal and meta-
physeal tissues was completely prevented in the pre-
sence of cycloheximide, an inhibitor of protein
synthesis, or DBR, an inhibitor of transcriptional activity
[56].
Synergistic effect of b-cryptoxanthin and zinc in
osteoblastogenesis
The effect of the combination with b-cryptoxanthin and
zinc or other factors [including 1,25-dihydroxyvitamin
D3 (VD3), 17 b-estradiol, genistein, or menaquinone-7
(MK-7)] on gene expression in osteoblastic MC3T3-E1
c e l l si se x a m i n e d[ 5 7 ] .C u l t u r ew i t hb-cryptoxanthin
(10
-7 or 10
-6 M) caused an increase in the expression of
Runx2 and alkaline phosphatase mRNAs in the cells.
This effect was not enhanced in the presence of VD3,1 7
b-estradiol, genistein, or MK-7. Culture with zinc sulfate
(10
-5 M) caused an increase in a 1 (I) collagen mRNA
expression, while it did not have a significant effect on
Runx2 or osteocalcin mRNA expression in the cells.
The effect of b-cryptoxanthin (10
-7 M) in increasing
Runx2 or a 1 (I) collagen mRNA expressions was
enhanced in the presence of zinc (10
-6 or 10
-5 M) [57].
Such an effect was not seen in the presence of cyclohex-
imide or DRB. The additive and/or synergistic effect of
H+ Lactic acid
TRACP  Cathepsin K Bone
TRACP
Cathepsin K
Gene expression Caspase 3
Bcl-2
Apoptosis
RANKL
RANK
TRAF6
Osteoclast
BCX
Nucleus
Figure 2 The molecular mechanism by which b-cryptoxanthin
(BCX) has suppressive effects on mature osteoclasts. BCX
inhibits osteoclast formation from mononuclear osteoclasts which
are mediated through RANKL and RANK signaling in bone marrow
culture systems. BCX stimulates apoptotic cell death by stimulating
the gene expression of caspase-3, an apoptosis-inducing enzyme,
and suppression of gene expression of Bcl-2, a rescue protein of
apoptosis. In addition, BCX suppresses the gene expression of
TRACP and cathepsin K, which are bone resorption-related enzymes,
and their enzyme activities in mature osteoclasts.
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blastic cells is partly resulted in newly synthesized pro-
tein components.
Zinc activates aminoacyl-tRNA synthetase, a rate-lim-
iting enzyme, in the translational process of protein
synthesis [53-55]. b-Cryptoxanthin can stimulate tran-
scriptional activity in osteoblastic cells [34]. It is specu-
lated that b-cryptoxanthin stimulates gene expression
and zinc increases translational activity in osteoblastic
cells. This may be important as a possible mechanism
by which zinc enhances the anabolic effect of b-cryptox-
anthin in osteoblastic cells.
Synergistic effect of b-cryptoxanthin and zinc in osteoclastic
cells
The effect of b-cryptoxanthin on osteoclastic cells
formed in the mouse marrow culture system in vitro
was found to enhance after culture with zinc [58]. Bone
marrow cells were isolated from mice. The macrophage
colony-stimulating factor (M-CSF)-dependent bone mar-
row cells were cultured in the presence of M-CSF and
RANKL for 96 hours. The osteoclastic cells formed were
further cultured for 24 or 72 hours in a medium con-
taining either vehicle, b-cryptoxanthin, zinc sulfate, or
b-cryptoxanthin plus zinc with or without M-CSF and
RANKL. The number of osteoclastic cells was decreased
after culture with the combination of b-cryptoxanthin
(10
-7 M) and zinc (10
-5 M )i nt h ep r e s e n c eo ra b s e n c e
of M-CSF and RANKL for 24 or 72 h as compared with
the value for b-cryptoxanthin or zinc [58].
The results of agarose gel electrophoresis showed the
presence of low-molecular weight deoxyribonucleic acid
(DNA) fragments of adherent cells cultured with b-cryp-
toxanthin plus zinc for 24 or 72 hours in the presence
of M-CSF and RANKL, indicating that the combination
of the two chemicals synergistically induces apoptotic
cell death [58].
b-Cryptoxanthin plus zinc-induced decrease in osteo-
clastic cells was inhibited in the presence of caspase-3
inhibitor [58]. Culture with b-cryptoxanthin plus zinc
for 24 or 72 hours caused an increase in caspase-3
mRNA expression in the presence or absence of M-CSF
and RANKL as compared with the value for each che-
mical alone. b-Cryptoxanthin plus zinc-induced increase
in caspase-3 mRNA expression was completely inhibited
in the presence of cycloheximide or DRB [58]. This sug-
gests that b-cryptoxanthin plus zinc-induced apoptotic
cell death is mediated through caspase-3 in osteoclastic
cells, and that b-cryptoxanthin plus zinc-enhanced cas-
pase-3 mRNA expression in osteoclastic cells is related
to newly synthesized protein synthesis.
The mRNA expression of tartrate-resistant acid phos-
phatase (TRACP) and cathepsin K was decreased after
culture with b-cryptoxanthin plus zinc in the presence
or absence of M-CSF and RANKL for 72 hours as com-
pared with b-cryptoxanthin or zinc alone [58].
Nuclear factor of activated T cells c1 (NFATc1)
mRNA expression was decreased after culture with b-
cryptoxanthin plus zinc in the presence or absence of
M-CSF and RANKL for 72 hours as compared with
each chemical alone, while NF-Bm R N Ae x p r e s s i o n
was not changed [58]. TRACP and cathepsin K are
enzymes that are involved in the degradation of bone
matrix components, and their enzyme activities are
increased in RANKL-stimulated bone resorption [45,46].
The combination of b-cryptoxanthin and zinc may have
a potent-suppressive effect on bone resorption.
NF-B and NFATc1 are molecules related to RANKL
signaling [45,46]. NFATc1 is a transcriptional factor that
enhances the gene expression of TRACP and cathepsin
K in osteoclasts, and the binding of NFATc1 to promo-
ter is involved in NF-B or AP-1 [45]. The suppression
of NFATc1 mRNA expression induced with the combi-
nation of b-cryptoxanthin and zinc may induce the
decrease in NF-B protein level. This may partly contri-
bute to the decrease in the TRACP or cathepsin K
mRNA expression caused by their combination.
Thus, the suppressive effects of b-cryptoxanthin on
osteoclastogenesis was demonstrated to enhance syner-
gistically in the presence of zinc, and also the combina-
tion of b-cryptoxanthin and zinc has potent suppressive
effects on osteoclastic cell function in vitro.
Anabolic effect of b-cryptoxanthin on bone is enhanced by
zinc in vivo
The effects of combined b-cryptoxanthin and zinc on
bone components in the femoral-diaphyseal (cortical
bone) and -metaphyseal (trabecular bone) tissues of rats
in vivo is shown [59]. Rats were orally administered
either vehicle, b-cryptoxanthin (50 or 100 μg/kg body
weight), zinc sulfate (1 or 5 mg Zn/kg), or their combi-
nation once a day for 7 days. Alkaline phosphatase
activity, DNA and calcium contents in the femaral-dia-
physeal tissues were not altered after the administration
of b-cryptoxanthin (50 μg / k g )o rz i n c( 1o r5m g / k g )
[59]. Combined administration of b-cryptoxanthin (50
μg/kg) and zinc (1 or 5 mg/kg) caused a synergistic
increase in alkaline phosphatase activity, DNA and cal-
cium contents in the diaphyseal tissues [59]. The effect
of b-cryptoxanthin (50 or 100 μg/kg) in increasing DNA
and calcium contents in the metaphyseal tissues was
enhanced after the combined administration of zinc (1
o r5m g / k g ) ,b u ti td i dn o th a v ea ne f f e c to nt h em e t a -
physeal components. The metaphyseal alkaline phospha-
tase activity has been found to increase markedly after
the administration of the combination of b-cryptox-
anthin (50 μg/kg) and zinc (1 or 5 mg/kg) [59]. Study
demonstrates that the oral administration of the
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enhances b-cryptoxanthin-induced anabolic effects on
the femoral tissues of rats in vivo. It is speculated that
the combination of b-cryptoxanthin and zinc has stimu-
latory effects on the gene expression, protein synthesis,
and cell proliferation in osteoblastic cells in rat femoral
tissues. This may contribute to their enhancing effect on
bone components in femoral tissues of rats in vivo.
The combination of b-cryptoxanthin plus zinc at a
lower concentration has a synergistic effect on bone
components in vivo. The combination of b-cryptox-
anthin plus zinc has potentiality in the prevention of
bone loss with aging. This finding is interested in
respect of the development of new supplement with the
composition of food factors that reveal a potent-anabolic
effect in prevention of osteoporosis. It also would be
useful to identify some of the foods that contain higher
levels of b-cryptoxanthin and zinc.
Preventive effect of b-cryptoxanthin on bone loss in vivo
As mentioned above, b-cryptoxanthin has been shown
to have a stimulatory effect on osteoblastic bone forma-
tion and an inhibitory effect on osteoclastic bone
resorption in vitro. Furthermore, the preventive effect of
b-cryptoxanthin on osteoporosis is demonstrated by
using animal models in vivo.
The anabolic effect of b-cryptoxanthin on bone com-
ponents in young and aged rats is examined. b-Cryptox-
anthin (100, 250, or 500 μg/kg body weight) was orally
administered once daily for 7 days to young male rats
[60]. The administration of b-cryptoxanthin (250, or 500
μg/kg) caused an increase in alkaline phosphatase activ-
ity, DNA and calcium contents in the femoral-diaphy-
seal and -metaphyseal tissues [61]. Such an effect was
also observed in the femoral tissues of aged (50-week-
old) female rats [62]. b-Cryptoxanthin has been shown
to have an anabolic effect on bone components in rats
in vivo.
b-Cryptoxanthin has been sown to have a preventive
effect on bone loss in the pathophysiologic state. Bone
loss is induced in streoptozotocin (STZ)-diabetic rats
[62]. Young rats received a single subcutaneous adminis-
tration of STZ (60 mg/kg body weight), and then the
animals were orally administered b-cryptoxanthin (50 or
100 μg/kg) once daily for 7 or 14 days. The administra-
tion of STZ caused a decrease in body weight and a sig-
nificant increase in serum glucose, triglyceride, and
calcium levels, indicating a diabetic state [62]. These
alterations were prevented after the administration of b-
cryptoxanthin (50 or 100 μg/kg) for 14 days [62]. Alka-
line phosphatase activity, DNA and calcium contents in
the femoral-diaphyseal and -metaphyseal tissues were
decreased in STZ-diabetic rats [62]. These decreases
were prevented after the administration of b-
cryptoxanthin (50 or 100 μg/kg) for 14 days [62]. Thus,
the intake of b-cryptoxanthin was found to have preven-
tive effects on STZ-diabetic state and bone loss in STZ-
diabetic rats.
Bone loss is induced after ovriectomy (OVX), which is
a model of postmenopausal osteoporosis. b-Cryptox-
anthin (50 or 100 μg/kg body weight) was orally admi-
nistered once daily for 3 months to OVX rats. The
analysis using peripheral quantitative computed tomo-
graphy shows that OVX induced a significant decrease
in mineral content and mineral density in the femoral-
diaphyseal and -metaphyseal tissues [63]. These
decreases were prevented after the administration of b-
cryptoxanthin (50 or 100 μg/kg). Moreover, OVX
induced a decrease in bone biochemical components.
These decreases are completely prevented after the
administration of b-cryptoxanthin (50 or 100 μg/kg). b-
Cryptoxanthin had a preventive effect on OVX-induced
bone loss in vivo [63].
Intake of dietary b-cryptoxanthin has a preventive effect
in menopausal women
The effect of b-cryptoxanthin on bone metabolism in
human is shown by using serum bone metabolic mar-
kers. Serum bone-specific alkaline phosphatase and g-
carboxylated osteocalcin are bone metabolic markers of
osteoblastic bone formation [64,65]. Serum bone
TRACP and N-telopeptides of type I collagen are meta-
bolic markers of osteoclastic bone resorption [66,67].
The effect of prolonged intake of juice prepared from
Satsuma mandarin (Citrus unshiu MARC) containing b-
cryptoxanthin is shown by using circulating biochemical
markers of bone metabolism in subjects including
menopausal woman [68-70].
Twenty-one volunteers (10 males and 11 females)
were divided into two groups of ten volunteers (5 males
and 5 females) and eleven volunteers (5 males and 6
females). Each group was given sequentially juice (192
ml) containing two different contents of b-cryptoxanthin
once a day for 28 or 56 days either a regular juice with
naturally occurring 802 μg b-cryptoxanthin/100 ml or a
reinforced juice containing 1500 μg b-cryptoxanthin/100
ml [68].
T h ei n t a k eo fr e g u l a rj u i c ef o r2 8o r5 6d a y si n
healthy subjects caused a significant increase in serum
g-carboxylated osteocalcin concentration, and the intake
for 56 days produces a decrease in serum bone TRACP
activity [68]. Moreover, the intake of the b-cyptoxanthin
reinforced juice for 28 or 56 days caused an increase in
serum g-carboxylated osteocalcin concentration and a
corresponding decrease in serum bone TRACP activity
and N-telopeptide of type I collagen [68]. These findings
s u g g e s tt h a tt h ei n t a k eo fb-cyptoxanthin reinforced
juice has a stimulatory effect on osteoblastic bone
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resorption in normal individuals [68].
The serum b-cyptoxanthin concentration was
increased after the intake of regular juice for 56 days
[69]. This increase was enhanced after the intake of b-
cyptoxanthin-reinforced juice. The intake of regular
juice or of b-cyptoxanthin-reinforced juice for 56 days
caused an increase in serum g-carboxylated osteocalcin
and a decrease in serum bone TRACP activity [69]. A
possible relationship between serum b-cyptoxanthin and
circulating g-carboxylated osteocalcin concentrations
was found by using the value obtained from all groups
f o rb e f o r ei n t a k ea n dw i t ht h ei n t a k eo fr e g u l a rj u i c e
and b-cyptoxanthin-reinforced juice. A negative relation-
ship between serum b- c y p t o x a n t h i nc o n c e n t a t i o na n d
circulating TRACP activity was observed [69]. This
study shows that a relationship between serum b-
cyptoxanthin and circulating bone metabolic markers is
found in healthy individuals with the intake of juice
containing b-cyptoxanthin.
Ninety volunteers, aged 27-65 years (19 men and 71
women), were enrolled in this study [70]. The seventy-
one females included 35 premenopausal women (ages,
27-50 years) and 36 menopausal women (ages, 46-65
years). Volunteers were divided into four groups; pla-
cebo juice without b-cyptoxanthin (5 men and 19
women), juice containing b-cyptoxanthin at 1.5 mg/200
ml of juice/day (4 men and 17 women), 3.0 mg/day (5
men and 17 women), and 6.0 mg/day (5 men and 18
women). Placebo or juice (200 ml) was ingested once a
day for 28 or 56 days.
Serum b-cryptoxanthin concentrations were increased
after the intake of juice containing b-cryptoxanthin (1.5,
3.0, or 6.0 mg/day) for 28 or 56 days, and the increases
were dose-dependent [65]. An increase in serum b-cryp-
toxanthin concentration was also observed at 28 days at
the end of intake, indicating that the carotenoid is stable
in the serum. Serum b-cryptoxanthin concentration was
in the range of 4.20 × 10
-7 Mt o4 . 8 9×1 0
-7 Mi nt h e
placebo groups. The intake of juice reinforced with b-
cryptoxanthin concentration at doses of 1.5, 3.0, or 6.0
mg/day increased the serum concentration to 2.43 × 10
-
6,4 . 0 6×1 0
-6,o r5 . 3 8×1 0
-6 M, respectively [70]. These
increases were about 5 or 10 fold as compared with the
value obtained before intake or after placebo intake. It
has been shown that the serum concentration of b-cryp-
toxanthin increased due to the consumption of vegeta-
ble juice in women from 1.3 × 10
-7 to 5.3 × 10
-7 M [33].
In ninety volunteers (aged 27-65 years), serum bone-
specific alkaline phosphatase activity was increased after
the intake of juice containing b-cryptoxanthin (3.0 or 6.0
mg/day) for 56 days as compared with the value obtained
before intake [70]. g-Carboxylated osteocalcin concentra-
tion was increased after the intake of juice containing b-
cryptoxanthin (3.0 or 6.0 mg/day) for 28 or 56 days as
compared with the value obtained before intake or after
the intake of placebo juice [70]. Serum TRACP activity
and type I collagen N-telopeptide concentration were
decreased after the intake of juice containing b-cryptox-
anthin (3.0 or 6.0 mg/day) for 28 or 56 days as compared
with the value obtained before intake or after intake of
placebo juice, and significant decreases were also seen
after the intake of 1.5 mg/day b-cryptoxanthin as com-
pared with the value obtained before intake [70].
In menopausal women (36 volunteers), bone-specific
alkaline phosphatase activity and g-carboxylated osteo-
calcin concentration were increased after the intake of
juice containing b-cryptoxanthin (3.0 or 6.0 mg/day) for
56 days as compared with the value obtained after pla-
cebo intake [70]. Also, this intake caused a decrease in
bone TRACP activity and type I collagen N-telopeptide
concentration. Thus, the prolonged intake of b-cryptox-
anthin-reinforced juice has been demonstrated to have
stimulatory effects on osteoblastic bone formation and
inhibitory effects on osteoclastic bone resorption in
menopausal women.
Meanwhile, serum calcium, inorganic phosphorous,
and parathyroid hormone (intact) were not changed
after the intake of b-cryptoxanthin-containing juice for
28 or 56 days. Other serum biochemical findings were
not changed after the intake of juice containing b-cryp-
toxanthin (3.0 or 6.0 mg/day) for 56 days. The safety of
b-cryptoxanthin in human is confirmed [70].
As mentioned above, the intake of juice reinforced
with b-cryptoxanthin (3.0 or 6.0 mg/day) has been
found to have an effect on circulating bone metabolic
markers in men, premenopausal women, and menopau-
sal women [70]. This indicates that the effects of b-cryp-
toxanthin in stimulating bone formation and inhibiting
bone resorption are present in both sexes. Interestingly,
the intake of juice reinforced with b-cryptoxanthin (3.0
or 6.0 mg/day) has been found to have effects on circu-
lating bone metabolic markers in menopausal women,
indicating that the supplementation of b-cryptoxanthin
h a sp r e v e n t i v ee f f e c t so nb o n e loss due to osteoporosis
in menopausal women. This preventive effect is obvious
at a dose of b-cryptoxanthin of 3.0 mg/day in menopau-
sal women. This dose may be suitable in the prevention
of osteoporosis in human subjects.
Thus, the intake of reinforced juice, which contains
more b-cryptoxanthin than regular juice, was demon-
strated to have a preventive effect on bone loss that
accompanies an increase in age.
b-Cryptoxanthin and bone health: Epidemiological
evidence
On the based on our findings, epidemiological studies
support the view that the intakes of fruit and vegetables
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osteoporosis [71-73].
The effect of dietary antioxidants on knee structure in a
cohort of healthy, middle-aged subjects with no clinical
knee osteoarthritis is reported [71]. Two hundred and
ninety-three healthy adults (mean age = 58.0 years) with-
out knee pain or knee injury were selected from an exist-
ing community-based cohort. The intake of antioxidant
vitamins and food sources by these individuals was esti-
mated from a food frequency questionnaire at baseline.
The cartilage volume, bone area, cartilage defects and
bone marrow lesions were assessed approximately 10
years later using magnetic resonance imaging. Higher
vitamin C intake was associated with a reduced risk of
bone marrow lesions and with a reduction in the tibial
plateau bone area. There was an inverse association
between fruit intake and the tibial plateau bone area and
between fruit intake and the risk of bone marrow lesions.
Neither fruit intake nor vitamin C intake was significantly
associated with the cartilage volume or cartilage defects.
Lutein and zeaxanthin intake was associated with a
decreased risk of cartilage defects, and vitamin E intake
tended to be positively associated with the tibial plateau
bone were only after adjusting for vitamin C intake. The
b-cryptoxanthin intake was inversely associated with the
tibial plateau bone area after adjusting for vitamin E
intake. These observations suggest a beneficial effect of
fruit consumption and vitamin C intake as they are
associated with a reduction in bone size and the number
of bone marrow lesions, both of which are important in
the pathogenesis of knee osteoarthritis [71].
Bone mineral density (BMD) in post-menopausal
female subjects has been shown to associate with serum
antioxidant carotenoids. A total of six hundred ninety-
nine subjects (222 males and 477 females) who had
received health examinations in the town of Mikkabi,
Shizuoka Prefecture, Japan, participated in the study
[72]. Radial BMD was measured by using dual-energy
X-ray absorptiometry. The associations of serum carote-
noid concentrations with the dadial BMD were evalu-
ated cross-sectionally. In male and pre-menopausal
female subjects, the six serum carotenoids were not
associated with the radial BMD. On the other hand, in
post-menopausal female subjects, serum b-cryptoxanthin
and b-carotene were weakly but positively correlated
with the radial BMD. After adjustment for confounders,
the odds ratio (OR) for the lowest quartile of BMD in
the high groups of serum b-cryptoxanthin against the
lowest quartile was 0.45 in post-menopausal female sub-
jects. However, this association was not significant after
further adjusting for intakes of minerals and vitamins.
Antioxidant carotenoids, especially b-cryptoxanthin, sig-
nificantly but partly associated with the radial BMD in
post-menopausal female subjects [72].
Seasonal variation of serum a-a n db-cryptoxanthin
and 25-OH-vitamin D3 in women with osteoporosis is
showed [73]. In six hundred fourty-four women with
osteoporosis, serum b-cryptoxanthin and 25-OH-vitamin
D3 showed a weak but significant correlation and exhib-
ited a complementary seasonal distribution [73]. Dietary
intake and serum levels of b-cryptoxanthin have been
inversely related to different bone and joint disorders
and in vitro and animal studies have shown that b-cryp-
toxanthin displays a unique anabolic effect on bone cal-
cification. Due to the emerging role of b-cryptoxanthin
in bone biology, this study was aimed to assess the
serum distribution and variability of b-cryptoxanthin
and their potential relation to 25-OH-vitamin D3 in
women with osteoporosis [73].
Overall, significant seasonal variations were found for
the three analyses and inter-individual variation was also
high (60-73%). b-Cryptoxanthin and 25-OH- vitamin D3
exhibited a marked complementary seasonal distribution
in serum, with vitamin D displaying the highest values
in summer and b-cryptoxanthin in winter.
Given the anabolic effect of b-cryptoxanthin on bone
calcification and its complementary seasonal distribution
with respect to 25-OH- vitamin D3, the potential role of
b-cryptoxanthin as a sustainable nutritional approach to
improving bone health deserves to be further evaluated
[73].
Dietary total carotenoids and osteoporosis prevention
Carotenoid b-cryptoxanthin was demonstrated to stimu-
late bone formation and to suppresse bone resorption in
vitro and in vivo studies. Effect of the associations of
total and individual carotenoid intake (a-carotene, b-
carotene, b-cryptoxanthin, lycopene, lutein, and zeax-
anthin) with incident hip fracture and nonvertebral
osteoporotic fracture are examined [74]. Three hundred
seventy men and 576 women (mean age, 75 ± 5 years)
from the Framingham Osteoporosis Study completed a
food frequency questionnaire (FFQ) in 1988-1989 and
were followed for hip fracture until 2005 and nonverteb-
ral fracture until 2003. Tertiles of carotenoid intake
were created from estimates obtained using the Willett
FFQ adjusting for total energy (residual method). HRs
were estimated using Cox-proportional hazards regres-
s i o n ,a d j u s t i n gf o rs e x ,a g e ,b o d ym a s si n d e x ,h e i g h t ,
total energy, calcium and vitamin D intake, physical
activity, alcohol, smoking, multivitamin use, and current
estrogen use. A total of 100 hip fractures occurred over
17 years of follow-up. Subjects in the highest textile of
total carotenoid intake had lower risk of hip fracture.
Subjects with higher lycopene intake had lower risk of
hip fracture and nonvertebral fracture. A weak protec-
tive trend was observed for total b-carotene for hip frac-
ture alone, but associations do not reach statistical
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with a-carotene, b-cryptoxanthin, or lutein plus zeax-
anthin. These findings suggest a protective role of sev-
eral carotenoids for bone health in older adults [74].
Antioxidant defenses may be compromised in osteo-
porotic women. Little is known about fruit and vegeta-
ble or carotenoid consumption among postmenopausal
women. The primary carotenoids in human serum are
a- and b-carotene, lycopene, b-cryptoxanthin, lutein and
zeaxanthin [75]. The interrelationships among serum
carotenoid concentrations, fruit and vegetable intake,
and osteoporosis in postmenopausal women (n = 59,
62.7 +/- 8.8 years) are shown [75]. Bone density was
assessed by dual energy x-ray absorptiometry (DEXA)
and osteoporosis diagnosis was based upon T-scores.
Serum samples (n = 53) and three-day diet records (n =
49) were analyzed. Logistic regression analyzed differ-
ences between carotenoids after adjusting for serum
retinol; supplement usage; milk, yogurt, fruit, and vege-
table intake; and body mass index. Pearson statistics
correlated carotenoids with specific fruit or vegetable
intake. Serum lycopene concentrations were lower in
the osteoporosis group than controls. b-Cryptoxanthin
intake was higher in the osteoporosis group. Total fruit
and vegetable intakes were correlated with serum lyco-
pene and b-cryptoxanthin [75].
Recent studies show that antioxidants may reduce the
risk of osteoporosis. The associations of BMD with diet-
ary patterns of antioxidant vitamins and carotenoids are
shown [76]. A total of 293 post-menopausal female sub-
jects who had received health examinations in the town
of Mikkabi, Shizuoka Prefecture, Japan, is participated in
the study [76]. Radial BMD was measured using DEXA.
Dietary patterns were identified on a selected set of anti-
oxidants through principal component factor analysis.
Three dietary patterns are identified. The “retinol” pat-
tern, characterized by notably high intakes of preformed
retinol, zeaxanthin, and vitamin E, is positively asso-
ciated with the risk for low BMD [76].
In contrast, the “ b-cryptoxanthin” pattern, character-
ized by notably high intakes of b-cryptoxanthin and
vitamin C, is negatively associated with low BMD [76].
The odds ratios for low BMD in the highest tertiles of
dietary intakes of preformed retinol, vitamin C, and b-
cryptoxanthin against the lowest tertiles are 3.22 [95%
confidence interval (CI), 1.38-7.51], 0.25 (CI, 0.10-0.66),
and 0.40 (CI, 0.17-0.92), respectively, after adjustments
for confounders [76]. However, negative associations of
vitamin C and b-cryptoxanthin with low BMD were not
significant after further adjustment for intake of b-cryp-
toxanthin or vitamin C, respectively [76]. Higher intakes
of both vitamin C and b-cryptoxanthin were signifi-
cantly associated with low BMD [76]. The findings sug-
gest the combination of vitamin C and b-cryptoxanthin
intakes might provide benefit to bone health in post-
menopausal Japanese female subjects. The combination
of vitamin C and b-cryptoxanthin may be associated
with radial BMD in post-menopausal women.
It is possible that the preventive effect of b-cryptox-
anthin on osteoporosis is enhanced with other carote-
noids and factors in foods. This may be important in
maintaining bone health in human life with food intake.
Conclusion
Bone mass is changed with increasing ages. Bone loss is
dramatically induced in postmenopausal women. Nutri-
tional and food factors may have a preventive role in
the decrease in bone mass with aging and pathophysio-
logic conditions. Among various carotenoids, b-cryptox-
anthin has been found to have a unique anabolic effect
on bone mass due to stimulating osteoblastic bone for-
mation and inhibiting osteoclastic bone resorption. b-
Cryptoxanthin modulates gene expression of various
proteins that involve in osteoblastic bone formation and
osteoclastic bone resorption. b-Cryptoxanthin may bind
to orpharn receptors, showing a novel mechanism of the
carotenoid in the aspect of bone fields. Further mechan-
ism of b-cryptoxanthin remains to be elucidated,
however.
The intake of dietary b-cryptoxanthin has been shown
to have preventive effect on bone loss in animal models
for osteoporosis and in menopausal women, suggesting
the possibility of pharmacological use of b-cryptoxanthin
in prevention and therapy of osteoporosis and other
bone diseases. The supplemental intake of b-cryptox-
anthin with higher dose may have a pharmacologic role
in the therapy of osteoporosis with clinical studies. In
addition, potential effects with b-cryptoxanthin deriva-
tives are expected in the development of new drug for
treatment of bone diseases.
In addition, the role of b-cryptoxanthin in bone health
has been also shown in human subjects with epidemio-
logical studies. The supplemental intake with the combi-
nation of b-cryptoxanthin and other nutritional factors
may has a potential effect in the maintaining of bone
health and decrease in bone loss.
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